Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
SKILCAB = Screening Kit for Lung Cancer Biomarkers Call: http://www.eurostars-eureka.eu/ Deadline: 30 Spetember 2010 Main Applicant: Farmafin, Italy – Prof. P Alecce Coordinator: Prof. Gennaro Ciliberto E-mail: [email protected] Introduction: Lung cancer is the most common cancer in the world. Lung cancers are highly heterogeneous malignancies, with tumors containing more than one subtype being very common. Similar to many other cancers, lung cancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes. Lung cancer has a complex picture of genetic changes found in lung cancer indicates that this pathology is not a single disease but is a composite of multiple diseases bearing activation of distinct signalling pathways which may participate in the subversion of cell growth and differentiation and resistance to apoptosis. This also explains why emerging therapies targeted to a specific gene, are efficient only in the subset of patients bearing specific mutational events involving that gene, or showing activation of the signalling pathway linked to that particular gene. Hence we believe that the future of lung cancer diagnosis and therapy is clearly that of pharmacogenomic or otherwise called personalized therapy, where initial diagnosis initially identifies for each patient the major genetic or epigenetic alterations leading to cell growth deregulation. Based on these considerations major efforts are currently directed to identify genetic and/or epigenetic events in lung cancer such as mutations, translocations, gene silencing, alternative splicing, MIR expression changes, validate them as new Biomarkers, and develop sophisticated novel diagnostic tools linked to them. SCOPE OF THE PROJECT: Improve cancer diagnosis and follow up to therapy by identifying novel biomarkers and generating relevant diagnostic tests useful for screening the peripheral blood of cancer patients SPECIFIC AIMS will be the identification of 3 types of Biomarkers for lung cancer: a) the identification and characterization of novel cancer-specific gene fusions deriving from translocations, chromosomal deletions, inversions; b) comprehensive analysis of alternative splicing; c) Lung cancer-specific MicroRNA changes. FINAL GOAL of the project is to develop novel diagnostic assays able to detect simultaneously a variety of driver genetic or transcriptional events taking place in lung cancer. The final format will be that of a multiplex custom microarray Field of the operation: Oncology, Lung Cancer, Diagnosis, Multianalytes Project details: Duration – up to 36 months Estimated budget: 2.4 MEuro (1.2 MEuro will be shared by SMEs, the other half will be shared between Academical Partners). Participants already involved: Participant Farmafin FARMA FIN University of USAMV Agricultural Scieneces and Veterinary Medicine of Cluj Oncological IOCN Institute of Cluj NIRI ICI Department of Human Genetics, University Medical School of Debrecen, H-4012 Debrecen Nagyerdei körút 98, Hungary UoD Dept of Clin & Mol UNIRO Type of Country Organiz ation SME Italy Scientific Contact Legal Representative Web page G. Ciliberto Dr. Alecce www.farm afin.com/ Dr. D. Pamfil www.usa mvcluj.ro SME Uni Rumania R. Suharoschi Hospital Rumania Researc h Institute Uni Rumania Dr. Neagoe L. Badea Hungary Prof. Sándor I. Dr. Al. Irimie www.unid eb.hu/ Biró Uni Italy M. Torrisi www.iocn. ro/ www.ici.ro/ Prof. M. Torrisi www.uniro Med, University of MA Rome La Sapienza RNA Biology UWE Group, School of Life Sciences, University of the West of England ma1.it/ Uni UK M. Ladomery PARTNER SEARCH: SMEs or large company with expertise in the field of micraoarrays, lung cancer biomarkers, omics technology, bioinformatics www.ladom erylab.org